How to adjust the dose of trametinib for optimal results

Trametinib is a highly selective oral MEK1/2 inhibitor that is commonly used to treat solid tumors carrying BRAF V600 mutations, especially in malignant melanoma, non-small cell lung cancer, thyroid cancer and other tumors. In clinical use, how to scientifically adjust the dose of trametinib is the key to ensuring both efficacy and reducing adverse reactions.

The usually recommended initial dose for adults is 2 mg taken orally once daily. It is not recommended to take it with food to avoid affecting bioavailability. However, due to significant individual differences among patients, common adverse reactions include rash, edema, decreased cardiac function, indigestion, oral mucositis, or interstitial lung lesions, and some patients may not be able to tolerate standard doses for a long time.

For this reason, dose tapering regimens have become an essential strategy. The first dose reduction to 1.5 mg orally once a day can still maintain a certain inhibitory effect. If symptoms persist, the dose can be further reduced to 1 mg once a day. In rare cases, some guidelines recommend reducing the third dose to 0.5 mg twice daily. However, it should be emphasized that the recommended interval between each dose adjustment should be no less than two weeks, and a clinical oncologist should make a comprehensive judgment based on the patient's laboratory test results and subjective discomfort reaction

. If the patient still develops grade 3 or above toxic reactions even after dose reduction, or has serious adverse events such as decreased cardiac function, ejection fraction, or impaired vision, permanent discontinuation of trametinib should be considered. In addition, trametinib is often used in combination with dabrafenib (BRAF inhibitor), and its dose adjustment should take into account the synergistic toxicity and pharmacokinetic interactions between the two drugs. Clinicians usually dynamically adjust dosages based on patient indicators to achieve precise medication. Therefore, dose individualization is not only an important guarantee to improve the efficacy of trametinib, but also an effective means to control its toxicity risk.

Reference materials:https://go.drugbank.com/drugs/DB08911